U.S. Markets closed
  • S&P Futures

    4,211.50
    +1.75 (+0.04%)
     
  • Dow Futures

    33,310.00
    +6.00 (+0.02%)
     
  • Nasdaq Futures

    13,327.00
    +15.75 (+0.12%)
     
  • Russell 2000 Futures

    1,977.70
    +1.40 (+0.07%)
     
  • Crude Oil

    93.90
    -0.44 (-0.47%)
     
  • Gold

    1,802.60
    -4.60 (-0.25%)
     
  • Silver

    20.23
    -0.12 (-0.61%)
     
  • EUR/USD

    1.0317
    -0.0009 (-0.0825%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2185
    -0.0018 (-0.1450%)
     
  • USD/JPY

    133.2330
    +0.2340 (+0.1759%)
     
  • BTC-USD

    23,966.45
    -397.76 (-1.63%)
     
  • CMC Crypto 200

    568.67
    -6.07 (-1.06%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,420.10
    +600.77 (+2.16%)
     

UPDATE 1-U.S. FDA extends review of Bristol Myers' heart disease drug

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

(Adds background, details of review)

Nov 19 (Reuters) - The U.S. health regulator has extended the review of Bristol Myers Squibb's oral heart disease drug candidate mavacamten, which the company acquired in its $13 billion buyout of MyoKardia last year.

The U.S. Food and Drug Administration (FDA) has not asked for any additional data and will now decide on the drug by April 28 next year, Bristol Myers said in a statement on Friday.

Mavacamten is intended for the treatment of obstructive hypertrophic cardiomyopathy, an inherited condition characterized by thickening of heart muscles, which is a common cause of sudden cardiac arrest in young people.

The FDA was originally set to decide on the drug in January, but informed the company earlier this month that it would need additional time to assess the treatment's safety information.

Mavacamten met the main and secondary goals in a late-stage study, demonstrating improvements in symptoms and quality of life for patients with the disease.

(Reporting by Amruta Khandekar; Editing by Aditya Soni)